CD8A and prostate carcinoma: In addition, upregulation of human leukocyte antigen (HLA)-DR on CD4+ and CD8+ T cells induced by combined immunotherapy with GVAX and ipilimumab of patients with advanced prostate cancer has also been reported [35].